Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:
about
Potency, selectivity, and consequences of nonselectivity of PDE inhibitionEffect of hydrogen sulphide-donating sildenafil (ACS6) on erectile function and oxidative stress in rabbit isolated corpus cavernosum and in hypertensive rats.Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidenceA Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.Nitric oxide in plants: an assessment of the current state of knowledge.Future therapies for pre-eclampsia: beyond treading water.Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction.Effect of sildenafil citrate on interleukin-1beta-induced nitric oxide synthesis and iNOS expression in SW982 cells.Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil.Inhibitory effect of sildenafil on rat duodenal contractility in vitro: putative cGMP involvement.Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats.Kinetics of a cellular nitric oxide/cGMP/phosphodiesterase-5 pathway.Effect of sildenafil on the isolated rat aortic rings.Sildenafil inhibits duodenal contractility via activation of the NO-K+ channel pathway.The NO/cGMP pathway in duodenal motor, mechano- and chemosensory responses to acid: A randomized, placebo-controlled study with sildenafil in healthy volunteers.Modulation of thioacetamide-induced liver fibrosis/cirrhosis by sildenafil treatment.
P2860
Q28269129-9AECFF2F-AC03-4730-982F-7DB9FA1A5179Q36682260-414B3CFA-84D7-47A9-B915-E122E3B1E416Q37018969-F9CCADBC-943D-4A37-ACFD-653EF48F4D11Q37820206-1781C35B-6DA3-4BBE-86D6-9776E6C4581EQ38078367-E15F4E6F-9D72-40FB-B4D9-8D5D33F7086EQ38151169-B190A24A-B601-4B1D-9C43-45D54438EEC0Q38235602-3F426822-F7F4-4E8E-B994-B70C90CF8948Q39967125-FC293080-4DDC-4448-BD07-221401993C6BQ40373695-4D1FE20D-F98B-46EC-820C-9654E5CC89FCQ42475001-21335F6C-E065-49B7-BAC5-78C50E3A3CB4Q43184339-4FB9F520-F87C-4366-8B07-64671BE90DD3Q44764454-71AF5013-D0F7-4DAA-A1B5-7C37BC797FF0Q44838264-E067405A-09CA-43B6-A9C6-7D3954A289E1Q46596421-04D76458-8E2A-477F-811E-9B52EE678A55Q46770816-A151FF9A-F657-4A0C-ADD9-4574DA791117Q48313861-16DABCAB-801F-4CC1-9B83-7D43B1D1E6C6Q54515289-5F7329FE-86FC-4598-B8B9-EBB36834B802
P2860
Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:
@ast
Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:
@en
type
label
Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:
@ast
Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:
@en
prefLabel
Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:
@ast
Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:
@en
P2093
P1476
Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:
@en
P2093
Goldstein I I
Moreland RB
P304
P356
10.1016/S1043-2760(98)00127-1
P50
P577
1999-04-01T00:00:00Z